As vascular endothelial growth factor (VEGF) pathway is strongly associated with increased LVSI, targeting the VEGF axis with anti-VEGF inhibitor may be an attractive approach in ovarian tumor expressing LVSI [25, 26, 27]. This evidence concerns the gene VEGFA and ovarian neoplasm.